Novel Strategies in Advanced Non–Small Cell Lung Cancer From ASCO 2022

Jonathan Goldman, MD


June 22, 2022

Dr Jonathan Goldman, from UCLA Health, discusses novel treatment strategies in advanced non–small cell lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting.

He begins with a substudy of the Lung-MAP trial, which demonstrated that ramucirumab plus pembrolizumab improved overall survival over standard of care. This is the first time that a treatment without a chemotherapy backbone has shown a survival benefit in the second-line setting.

Next, Dr Goldman reviews updated results from CHRYSALIS-2, in which a combination of amivantamab and lazertinib showed antitumor activity in patients with advanced EGFR-mutant NSCLC who had progressed on osimertinib and platinum-based chemotherapy.

Dr Goldman goes on to discuss a phase 1/2a trial in which CLN-801, a novel EGFR tyrosine kinase inhibitor, achieved an encouraging and durable objective response rate in patients with EGFR exon 20 insertion mutations.

He then reports on the results of two trials of telisotuzumab vedotin, one as monotherapy and one with osimertinib, and concludes with an analysis showing that patients with advanced NSCLC who undergo comprehensive genotyping have an improved overall survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.